VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022

News
VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022
Partager cet article
VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022
Texte

VitaDX is proud to announce that the abstract of its first clinical trial "VISIOCYT 1: Artificial Intelligence for the Diagnosis of Urothelial Bladder Carcinoma" has been selected for presentation at ASCO 2022.


Précédent
Suivant